ABOUT US
We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry.
Traditional drug design is limited
At Congruence, we are able to move beyond historically static drug discovery processes towards truly predictive models where the pathogenesis of disease can be corrected in silico at unprecedented speed and accuracy.
Recent Press Releases
Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime
Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson’s Disease with GBA1 Mutations at the GBA1 Meeting 2025
https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime
Ground-breaking
discovery engine
Revenir™ allows us to see proteins as others can’t – in their full and dynamic state. We generate and capture the biophysical properties of the full spectrum of protein shapes, an ensemble of protein conformers, derived from a single amino acid sequence.